In NGP-Fluc mice, at earlier time points of treatment (up to days 16 and 23), the tumor burden (log-transformed tumor flux) of mice treated with anti-CCL2 antibody combined with etoposide was significantly inhibited over time compared to mice treated with PBS (p < 0.001), anti-CCL2 antibody alone (p < 0.001), or etoposide alone (p = 0.015) (Supplementary Table 2). The gene discussed is CCL2; the disease is neoplasm.